Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

A novel drug combination targeting LSD1 and GSK3 shows promise in treating acute myeloid leukemia by promoting cell ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both ...

Researchers examine how salutogenesis, the active production of health through immune resilience, resists disease.

Unrepresentative pre-clinical models contribute to poor translation of glioblastoma research. We present an ...

Vitamin D supplements may help decrease the risk of colorectal cancer and improve survival for people with colorectal cancer, ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, ...